Fosaprepitant dimeglumine + Fosaprepitant Placebo + Dexamethasone + Ondansetron + Dexamethasone Placebo + Ondansetron Placebo + Rescue Therapy
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy-Induced Nausea and Vomiting (CINV)
Conditions
Chemotherapy-Induced Nausea and Vomiting (CINV)
Trial Timeline
Sep 24, 2012 โ Nov 3, 2014
NCT ID
NCT01594749About Fosaprepitant dimeglumine + Fosaprepitant Placebo + Dexamethasone + Ondansetron + Dexamethasone Placebo + Ondansetron Placebo + Rescue Therapy
Fosaprepitant dimeglumine + Fosaprepitant Placebo + Dexamethasone + Ondansetron + Dexamethasone Placebo + Ondansetron Placebo + Rescue Therapy is a phase 3 stage product being developed by Merck for Chemotherapy-Induced Nausea and Vomiting (CINV). The current trial status is completed. This product is registered under clinical trial identifier NCT01594749. Target conditions include Chemotherapy-Induced Nausea and Vomiting (CINV).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01594749 | Phase 3 | Completed |
Competing Products
20 competing products in Chemotherapy-Induced Nausea and Vomiting (CINV)